Vadastuximab disitamab vedotin antibody-drug conjugate representing a significant advancement in the approach of acute myeloid leukemia (AML). This groundbreaking therapy specifically targets CD33, a protein frequently found on leukemic cells . The action involves binding to CD33, leading to both cellular cytotoxicity and enhanced immune-mediated k

The arrival of amivantamab offers a exciting advance for patients battling cancers with c-MET dysregulation. This innovative molecule, a selective agent of dual MET kinase plus human epidermal growth factor receptor 2 (HER2), showed encouraging results in research trials, particularly in patients whose tumors possess exhibitable c-MET alterations 1